Cholera (Vibrio cholerae)
Purpose
The purpose of these policy guidelines is to
recommend procedures for handling potential biological threats of Cholera
(Vibrio cholerae).
Description of AgentlSyndrome
Cholera is an acute bacterial enteric disease.
Although more than 100 serotypes of V. cholera exist, only 01 and 0139 are
associated with the clinical syndrome of cholera. Cholera is considered a
Category B Biological Agent. This guideline addresses only serogroups 01 and
0139.
Transmission
Through ingestion of food or water contaminated
directly or indirectly with feces or vomitus of infected person.
Incubation Period
1. Ranges from a few hours to 5 days
(usually 2-3 days)
2. Period of Communicability:
Presumably as long as stools are positive, usually only a few days after
recovery occasionally carrier state may persist for several months. Antibiotics
known to be effective against infecting strains shorten period of
communicability.
Signs and Symptoms
1. Most infections are asymptomatic.
2. Clinical illness ranges from mild
diarrhea to profuse, painless, dehydrating diarrhea that can be fatal in 2-3
hours if untreated.
3. Vomiting may also occur.
Isolation of organism in stool or vomitus
Treatment
1. Rehydration and treatment of
complications
2.
Antimicrobial
|
|
Dose |
|
|
Drug |
Adult |
Children |
|
Tetracycline |
500 mg qid for 3 d |
50 mg/kg of body weight qid for 3 d |
|
Doxycycline |
300 mg as a single dose |
Not evaluated |
|
Cotrimoxazole |
160 mg of trimethoprim 800 mg of sulfamethoxazole bid for 3 d |
8 mg of trimethoprim 40 mg of sulfamethozazole/kg * divided in 2 doses
for 3 d |
|
Norfloxacin |
400 mg bid for 3 d |
Not recommended |
|
Ciproflaxacin |
250 mg/d for 3 d 1 g as a single dose |
Not recommended |
From Seas C, Dupont HL, Valdez LM, et al. Practical guidelines for the treatment of cholera. Drugs 1996; 51:966-973
Since individual strains of V.cholerae may be
resistant to some antimicrobials, knowledge of sensitivity patterns of local
strains, if available, should be used to guide the choice of antimicrobial
therapy.
1. Treatment of contacts:
Surveillance of persons who shared food and drink with cholera patients for 5
days from last exposure. If there is evidence or high likelihood of secondary
transmission, treat household members with:
a) Adults: Tetracycline 500mg QID or Doxycycline
300mg QD x 3 days
b) Children: Tetracycline 50mg/kg/day
in 4 divided doses or a single dose of doxycycline 6mg/kg for 3 days.
2. Vaccine: A vaccine is
available that offers partial protection (50%) for short duration (3-6 months)
however it is not recommended.
3. Immunization of contacts is not
indicated
Control Measures and Decontamination
1. Standard Precautions
2. Use contact precautions for
diapered or incontinent children under 6 years of age
3. Education of those at risk to seek
treatment without delay
Notification
Internal: At hospital
notify_______________________________
External: All suspected cases of suspected Cholera are
Class Al Reportable and should be reported immediately to the Local Health Department
who will then contact the State Health Department and/or CDC.
Lab
Due to potential risks associated with handling
infectious materials, laboratory testing should be the minimum necessary for
diagnostic evaluation and patient care. Laboratory specimens should be placed
in plastic bags (with a biohazard label) that are sealed, and then transported
in clearly labeled, durable, leak proof containers directly to the specimen
handling area of the laboratory. Care should be taken not to contaminate the
external surfaces of the container. Lab personnel should be notified of what
they are handling. Bio-Safety Level 2 should be used for handling specimens.
References
1. Chin, J. Control of Communicable
Diseases Manual 17th Edition, 2000. American Public Health Association.
Washington D.C.
2. Infectious Disease Control Manual.
Ohio Department of Health 11/99.
3. Mandell, GL, Bennett, JE, Dolin, R,
Eds; Principles and Practices of Infectious Diseases. Philadelphia: Churchill
Livingstone; 2000.
Initially Prepared by
The Akron Regional Hospital
Association
Emergency Preparedness
Subcommittee
August 20, 2002